Vaxart to Host Webcast with Critical Opinion Leaders to Speak about the Effectively becoming Impact and Illness Burden for Norovirus

Vaxart, Inc.

Organization to provide a detailed overview of its norovirus clinical program

Webcast to be held on March 28, 2023 at 1:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) at present announced it will host a crucial opinion leader video webcast on the properly becoming and economic impact and illness burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET.

The webcast will function presentations by prominent norovirus illness authorities Jan Vinjé, Ph.D., Head, National Calicivirus Laboratory, Centers for Illness Manage &amp Prevention, and Sarah Bartsch, Project Director, Public Effectively becoming Informatics, Computational, and Operations Evaluation, Evaluation Foundation of the City University of New York.

In addition, Vaxart management will provide a detailed overview of the Company’s investigational norovirus oral pill vaccine program, such as its two present Phase two clinical trials:

• An ongoing Phase two GI.1 norovirus challenge study measuring the efficacy and safety of our norovirus vaccine candidate. The study is also produced to establish a correlate of protection involving immune responses to the vaccine and a reduction in danger of norovirus infection and / or intense gastroenteritis. The Organization expects to report topline data from this study in Q3 2023.

• A Phase two dose-ranging study of Vaxart’s bivalent norovirus oral vaccine candidate is produced to establish a vaccine dose for a potential Phase 3 clinical trial. The Organization expects to report topline data from this study in mid-2023.

To register for the webcast, please click ideal right here. A replay of the webcast will be obtainable on the Company’s internet web page at www.vaxart.com following the conclusion of the occasion.

About the KOLs

Jan Vinjé, Ph.D.
Dr. Vinjé is head of the National Calicivirus Laboratory and Director of CaliciNet at the Centers for Illness Manage and Prevention (CDC) in Atlanta, GA. Dr. Vinjé received his Ph.D. degree at the University of Utrecht, the Netherlands, in 1999. Quickly just after finding a postdoctoral fellowship and an appointment as investigation assistant professor at the University of North Carolina in Chapel Hill, he joined CDC in 2006. Much more than the earlier ten years, he has served on several program advisory committees from several European investigation projects (FP6, FP7). He is serving as technical expert on the norovirus subcommittee of the National Advisory Committee on Microbiological Criteria for Foods and is a member of the International Committee on Taxonomy of Viruses study groups on Caliciviridae (chair as of 2014) and Astroviridae. He is at present a member of the editorial board of the Journal of Clinical Microbiology and associate editor of the journal Meals and Environmental Virology, and he serves as an ad hoc reviewer for many larger-impact journals. Dr. Vinjé has published much more than a single hundred peer-reviewed publications and several book chapters. His investigation interests involve all components of viral gastrointestinal illness, such as detection, characterization, and prevention and manage of norovirus infections.

Story continues

Sarah M. Bartsch, MPH
Ms. Bartsch is a Project Director and Senior Analyst with Public Effectively becoming Informatics, Computational, and Operations Evaluation (PHICOR), the Artificial Intelligence, Modeling, and Informatics for Nutrition Guidance and Systems (AIMINGS) Center, and the Center for Sophisticated Technologies and Communication in Effectively becoming (CATCH), headquartered at the City University of New York (CUNY) Graduate College of Public Effectively becoming and Effectively becoming Policy. She has been a aspect of the group due to the fact August of 2009 and has much more than a decade of sensible knowledge creating use of systems approaches and establishing mathematical and computational models to assist a wide wide variety of choice makers in public properly becoming. Bartsch has authored much more than 95 scientific publications, such as further than 30 as quite 1st author.

About Vaxart 
Vaxart is a clinical-stage biotechnology organization establishing a wide variety of oral recombinant vaccines mainly primarily based on its proprietary delivery platform. Vaxart vaccines are produced to be administered creating use of tablets that can be stored and shipped with out the will need of refrigeration and get rid of the danger of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to present recombinant vaccines, positioning the organization to build oral versions of at present marketed vaccines and to style recombinant vaccines for new indications. Vaxart’s improvement applications at present involve pill vaccines produced to safeguard against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as effectively as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s quite 1st immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technologies and creations for oral vaccination creating use of adenovirus and TLR3 agonists.

Note Relating to Forward-Hunting Statements
This press release consists of forward-looking statements that involve substantial dangers and uncertainties. All statements, other than statements of historical specifics, integrated in this press release regarding Vaxart’s tactic, prospects, plans and objectives, rewards from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements might properly be accompanied by such words as “definitely ought to,” “assume,” “could,” “potential,” “will,” “anticipated,” “anticipate,” “plan,” and other words and terms of associated which indicates. Examples of such statements involve, but are not restricted to, statements relating to Vaxart’s capability to build and commercialize its item candidates, such as its vaccine booster goods Vaxart’s expectations regarding clinical rewards and trial data and Vaxart’s expectations with respect to the effectiveness of its item candidates. Vaxart might properly not in truth attain the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you definitely ought to not place undue reliance on these forward-looking statements. Actual rewards or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Several very important variables could lead to actual rewards or events to differ materially from the forward-looking statements that Vaxart tends to make.

Please also refer to the dangers described in the “Danger Variables” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as essential by law.

Contacts

Investor Relations:

Andrew Blazier

FINN Partners

IR@vaxart.com

(646) 871-8486